iptacopan
Selected indexed studies
- Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy. (N Engl J Med, 2025) [PMID:39453772]
- Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria. (N Engl J Med, 2024) [PMID:38477987]
- Iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria. (Expert Opin Pharmacother, 2024) [PMID:39404123]
_Worker-drafted node — pending editorial review._
Connections
iptacopan is a side effect of
Sources
- Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy. (2025) pubmed
- Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria. (2024) pubmed
- Iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria. (2024) pubmed
- Iptacopan. (2006) pubmed
- Iptacopan: First Approval. (2024) pubmed
- Iptacopan Efficacy and Safety to Treat Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Meta-Analysis. (2024) pubmed
- Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy. (2024) pubmed
- Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria. (2024) pubmed
- Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial. (2022) pubmed
- Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study. (2022) pubmed